DelveInsight’s, “Diabetes Pipeline Insights, 2021,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Diabetes, is a metabolic disease that causes high blood sugar. The hormone insulin moves sugar from the blood into your cells to be stored or used for energy. With diabetes, your body either doesn’t make enough insulin or can’t effectively use the insulin it does make.
Untreated high blood sugar from diabetes can damage your nerves, eyes, kidneys, and other organs.
There are a few different types of diabetes:
- Type 1 diabetes is an autoimmune disease. The immune system attacks and destroys cells in the pancreas, where insulin is made. It’s unclear what causes this attack. About 10 percent of people with diabetes have this type.
- Type 2 diabetes occurs when your body becomes resistant to insulin, and sugar builds up in your blood.
- Prediabetes occurs when your blood sugar is higher than normal, but it’s not high enough for a diagnosis of type 2 diabetes.
- Gestational diabetes is high blood sugar during pregnancy. Insulin-blocking hormones produced by the placenta cause this type of diabetes.
Request for a free Sample report: https://www.delveinsight.com/sample-request/diabetes-pipeline-insight
Some of Diabetes Companies:
- Daewoong Tradipitant
- Janssen Biotech
- Zealand Pharma
- Provention Bio
- BioRestorative Therapies
- Elevian
- Kamada
- Adocia
- Oramed Pharmaceuticals
- ImCyse
- Histogen
- Novo Nordisk
- Enthera
- ActoBio Therapeutics
- Japan Tobacco
- Avotres
- And Many Others
Request for a free Sample report: https://www.delveinsight.com/sample-request/diabetes-pipeline-insight
Some of Diabetes Therapies:
- Enavogliflozin
- Golimumab
- Dasiglucagon
- Teplizumab
- BRTX-100
- rGDF11
- Alpha-1 antitrypsin
- BC 222 Insulin Lispro
- Insulin oral
- IMCY-0098
- Emricasan
- Insulin icodec
- ENT-001
- AG019
- JTT-662
- AVT-001
Request for a free Sample report: https://www.delveinsight.com/sample-request/diabetes-pipeline-insight
Table of Contents:
Introduction
Executive Summary
Diabetes: Overview
Pipeline Therapeutics
Therapeutic Assessment
Diabetes – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Diabetes Collaboration Deals
Late Stage Products (Phase III)
• Comparative Analysis
Enavogliflozin: Daewoong
Mid Stage Products (Phase II)
• Comparative Analysis
Golimumab: Janssen Biotech
Early Stage Products (Phase II/I)
• Comparative Analysis
IMCY-0098: ImCyse
Pre-clinical and Discovery Stage Products
• Comparative Analysis
ENT-001: Enthera
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Diabetes Key Companies
Diabetes Key Products
Diabetes- Unmet Needs
Diabetes- Market Drivers and Barriers
Diabetes- Future Perspectives and Conclusion
Diabetes Analyst Views
Diabetes Key Companies
Appendix
Request for Detailed TOC: https://www.delveinsight.com/sample-request/diabetes-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/diabetes-pipeline-insight